查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1726168

糖尿病前期市场规模、份额、趋势分析报告：按药物类别、年龄层、地区和细分市场预测，2025 年至 2030 年

Prediabetes Market Size, Share & Trends Analysis Report By Drug Class (Diguanide, Thiazolidinediones, Glucagon-like Peptide-1 Agonists (GLP-1), DPP-4 Inhibitors), By Age Group (Children, Adult, Elderly), By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 134 Pages | 商品交期: 2-10个工作天内

价格

糖尿病前期市场的成长与趋势

根据 Grand View Research, Inc. 的新报告，预计到 2030 年全球糖尿病前期市场规模将达到 5.857 亿美元。

预计 2025 年至 2030 年间，市场复合年增长率将达到 10.9%。推动市场成长的因素有很多。主要驱动因素之一是糖尿病前期盛行率的上升和肥胖率的增加。肥胖与糖尿病的发展有关。例如，根据圣路易斯华盛顿大学 2023 年 6 月的一项研究，美国有超过 3700 万人患有糖尿病，其中超过 40% 的人肥胖，这种情况与多达一半的糖尿病病例有关。据估计，大约有 9,600 万美国人（约占成年人的三分之一）患有糖尿病前期。肥胖通常与久坐的生活方式和不良的饮食习惯有关，是导致糖尿病前期的重要危险因子。糖尿病前期患者的增多与全球肥胖症的流行同时发生，显示了这两个健康问题之间的关联。

此外，遗传倾向和家族病史也扮演重要角色。虽然生活方式起着很大的作用，但遗传因素也会影响个人对糖尿病前期的易感性，使某些人群更容易患上糖尿病前期。

糖尿病前期市场报告重点

  • 根据药物类别，双胍类药物将在 2024 年占据市场主导地位，销售额份额最大，为 78.8%。Metformin属于双胍类药物，是糖尿病的第一线治疗药物。Metformin是用于治疗和减缓糖尿病前期进展的最常用的仿单标示外用药。
  • 从年龄层来看，成年人群体在 2024 年占据市场主导地位，销售额占最大。成年人久坐不动和易患病的生活方式日益盛行是这一年龄层的主要成长要素。糖尿病前期盛行率的提高和人们认识的提高正在推动这一领域的成长。
  • 由于先进的医疗基础设施、较高的认知度以及较高的临床测试研究活动，北美在 2024 年占据了市场主导地位，收入份额为 41.3%。该地区拥有先进且强大的研究基础设施。社区计画和支持团体鼓励糖尿病前期患者做出可持续的生活方式改变，例如健康饮食和定期进行体能活动。

目录

第一章调查方法与范围

第二章执行摘要

3. 糖尿病前期市场变数、趋势与范围

  • 市场体系展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 商业环境分析
    • 产业分析—波特五力分析
    • PESTLE分析

4. 糖尿病前期市场：药物类别业务分析

  • 2024 年及 2030 年药品类别市场占有率
  • 药品类别细分仪表板
  • 2018 年至 2030 年药品类别市场规模、预测与趋势分析
  • 双胍
  • 胰岛素增敏剂
  • Glucagon-Like Peptide-1促效剂（GLP-1）
  • SGLT2抑制剂
  • DPP-4抑制剂
  • 其他的

第五章糖尿病前期市场：依年龄组别进行的业务分析

  • 2024 年及 2030 年各年龄层市场占有率
  • 年龄层细分仪表板
  • 市场规模、预测及趋势分析（依年龄组，2018-2030 年）
  • 幼儿（12-18岁）
  • 成人（18-49岁）
  • 老年人（50岁或以上）

第六章 糖尿病前期市场：区域估计与趋势分析

  • 2024 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 2018-2030年市场规模及预测趋势分析
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 挪威
    • 瑞典
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章 竞争态势

  • 参与者概览
  • 企业市场分析
  • 公司分类
  • 战略地图
  • 公司简介/上市公司
    • Novo Nordisk A/S
    • ValbIoTis
    • RESVERLOGIX
    • Caelus Health
    • Scimar
    • Boston Pharmaceuticals
    • APHAIA PHARMA AG
    • AstraZeneca
    • Bristol-Myers Squibb Company
    • Pfizer Inc.
Product Code: GVR-4-68040-221-4

Prediabetes Market Growth & Trends:

The global prediabetes market size is anticipated to reach USD 585.7 million by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 10.9% from 2025 to 2030. Several factors drive the market growth. One of the main factors driving is the rising prevalence of prediabetes and increasing obesity rates. Obesity correlates with the development of diabetes. For instance, according to Washington University in St. Louis in June 2023, over 37 million individuals in the U.S. are affected by diabetes, with over 40% of them experiencing obesity, a condition associated with up to half of all diabetes cases. It is estimated that approximately 96 million Americans, constituting roughly one-third of adults, are living with prediabetes. Obesity, often linked with sedentary lifestyles and poor diet, is a significant risk factor for developing prediabetes. The rise in prediabetes cases has coincided with the global obesity epidemic, demonstrating the connection between these two health problems.

Moreover, genetic predisposition and family history also contribute significantly. While lifestyle factors play a predominant role, genetic factors can influence an individual's susceptibility to developing prediabetes, making specific populations more prone to the condition.

Prediabetes Market Report Highlights:

  • Based on the drug class, the diguanide segment led the market with the largest revenue share of 78.8% in 2024. Metformin, a drug under the diguanide class is the first choice of drug for the treatment of prediabetes. It is the most commonly prescribed off-label drug for the treatment and slowing down the progression of prediabetes.
  • Based on the age group, the adult segment led the market with the largest revenue share in 2024. The increasing sedentary and disease-causing lifestyle among adults is the primary growth factor for this age group segment. The increasing prevalence of prediabetes along with increased awareness are driving the growth of this segment.
  • North America dominated the market with the revenue share of 41.3% in 2024, owing to the advanced healthcare infrastructure, high awareness, and high research activities for clinical trials. The region offers an advanced and strong research infrastructure. Community-based programs and support groups empower individuals with prediabetes to make sustainable lifestyle changes, such as healthy eating and regular physical activity.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Age Group
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Prediabetes Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrant
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Prediabetes Market: Drug Class Business Analysis

  • 4.1. Drug Class Market Share, 2024 & 2030
  • 4.2. Drug Class Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, By Drug Class, 2018 to 2030 (USD Million)
  • 4.4. Diguanide
    • 4.4.1. Diguanide Market, 2018 - 2030 (USD Million)
  • 4.5. Thiazolidinediones
    • 4.5.1. Thiazolidinediones Market, 2018 - 2030 (USD Million)
  • 4.6. Glucagon-like peptide-1 agonists (GLP-1)
    • 4.6.1. Glucagon-like peptide-1 agonists (GLP-1) Market, 2018 - 2030 (USD Million)
  • 4.7. SGLT2 inhibitors
    • 4.7.1. SGLT2 inhibitors Market, 2018 - 2030 (USD Million)
  • 4.8. DPP-4 inhibitors
    • 4.8.1. DPP-4 inhibitors Market, 2018 - 2030 (USD Million)
  • 4.9. Others
    • 4.9.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Prediabetes Market: Age Group Business Analysis

  • 5.1. Age Group Market Share, 2024 & 2030
  • 5.2. Age Group Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, By Age Group, 2018 to 2030 (USD Million)
  • 5.4. Children (12-18 years)
    • 5.4.1. Children (12-18 years) Market, 2018 - 2030 (USD Million)
  • 5.5. Adults (18-49)
    • 5.5.1. Adults (18-49) Market, 2018 - 2030 (USD Million)
  • 5.6. Elderly (50+)
    • 5.6.1. Elderly (50+) Market, 2018 - 2030 (USD Million)

Chapter 6. Prediabetes Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2018 to 2030
  • 6.4. North America
    • 6.4.1. North America Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamic
      • 6.4.2.2. Regulatory Framework
      • 6.4.2.3. Competitive Insights
      • 6.4.2.4. U.S. Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamic
      • 6.4.3.2. Regulatory Framework
      • 6.4.3.3. Competitive Insights
      • 6.4.3.4. Canada Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamic
      • 6.4.4.2. Regulatory Framework
      • 6.4.4.3. Competitive Insights
      • 6.4.4.4. Mexico Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamic
      • 6.5.2.2. Regulatory Framework
      • 6.5.2.3. Competitive Insights
      • 6.5.2.4. UK Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamic
      • 6.5.3.2. Regulatory Framework
      • 6.5.3.3. Competitive Insights
      • 6.5.3.4. Germany Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamic
      • 6.5.4.2. Regulatory Framework
      • 6.5.4.3. Competitive Insights
      • 6.5.4.4. France Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamic
      • 6.5.5.2. Regulatory Framework
      • 6.5.5.3. Competitive Insights
      • 6.5.5.4. Italy Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamic
      • 6.5.6.2. Regulatory Framework
      • 6.5.6.3. Competitive Insights
      • 6.5.6.4. Spain Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamic
      • 6.5.7.2. Regulatory Framework
      • 6.5.7.3. Competitive Insights
      • 6.5.7.4. Denmark Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.8. Norway
      • 6.5.8.1. Key Country Dynamic
      • 6.5.8.2. Regulatory Framework
      • 6.5.8.3. Competitive Insights
      • 6.5.8.4. Norway Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.9. Sweden
      • 6.5.9.1. Key Country Dynamic
      • 6.5.9.2. Regulatory Framework
      • 6.5.9.3. Competitive Insights
      • 6.5.9.4. Sweden Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamic
      • 6.6.2.2. Regulatory Framework
      • 6.6.2.3. Competitive Insights
      • 6.6.2.4. Japan Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamic
      • 6.6.3.2. Regulatory Framework
      • 6.6.3.3. Competitive Insights
      • 6.6.3.4. China Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamic
      • 6.6.4.2. Regulatory Framework
      • 6.6.4.3. Competitive Insights
      • 6.6.4.4. India Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. South Korea
      • 6.6.5.1. Key Country Dynamic
      • 6.6.5.2. Regulatory Framework
      • 6.6.5.3. Competitive Insights
      • 6.6.5.4. South Korea Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.6. Australia
      • 6.6.6.1. Key Country Dynamic
      • 6.6.6.2. Regulatory Framework
      • 6.6.6.3. Competitive Insights
      • 6.6.6.4. Australia Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamic
      • 6.6.7.2. Regulatory Framework
      • 6.6.7.3. Competitive Insights
      • 6.6.7.4. Thailand Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamic
      • 6.7.2.2. Regulatory Framework
      • 6.7.2.3. Competitive Insights
      • 6.7.2.4. Brazil Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamic
      • 6.7.3.2. Regulatory Framework
      • 6.7.3.3. Competitive Insights
      • 6.7.3.4. Argentina Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamic
      • 6.8.2.2. Regulatory Framework
      • 6.8.2.3. Competitive Insights
      • 6.8.2.4. South Africa Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamic
      • 6.8.3.2. Regulatory Framework
      • 6.8.3.3. Competitive Insights
      • 6.8.3.4. Saudi Arabia Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamic
      • 6.8.4.2. Regulatory Framework
      • 6.8.4.3. Competitive Insights
      • 6.8.4.4. UAE Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamic
      • 6.8.5.2. Regulatory Framework
      • 6.8.5.3. Competitive Insights
      • 6.8.5.4. Kuwait Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Novo Nordisk A/S
      • 7.5.1.1. Participant's Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Valbiotis
      • 7.5.2.1. Participant's Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. RESVERLOGIX
      • 7.5.3.1. Participant's Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Caelus Health
      • 7.5.4.1. Participant's Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Scimar
      • 7.5.5.1. Participant's Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Boston Pharmaceuticals
      • 7.5.6.1. Participant's Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. APHAIA PHARMA AG
      • 7.5.7.1. Participant's Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. AstraZeneca
      • 7.5.8.1. Participant's Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. Bristol-Myers Squibb Company
      • 7.5.9.1. Participant's overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Product Benchmarking
      • 7.5.9.4. Strategic Initiatives
    • 7.5.10. Pfizer Inc.
      • 7.5.10.1. Participant's Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Product Benchmarking
      • 7.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Prediabetes Market, by Region, 2018 - 2030 (USD Million)
  • Table 4 Global Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 5 Global Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 6 North America Prediabetes Market, by Country, 2018 - 2030 (USD Million)
  • Table 7 North America Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 8 North America Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 9 U.S. Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 10 U.S. Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 11 Canada Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 12 Canada Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 13 Mexico Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 14 Mexico Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 15 Europe Prediabetes Market, by Country, 2018 - 2030 (USD Million)
  • Table 16 Europe Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 17 Europe Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 18 U.K. Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 19 U.K. Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 20 Germany Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 21 Germany Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 22 France Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 23 France Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 24 Italy Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 25 Italy Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 26 Spain Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 27 Spain Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 28 Denmark Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 29 Denmark Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 30 Norway Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 31 Norway Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 32 Sweden Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 33 Sweden Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific Prediabetes Market, by Country, 2018 - 2030 (USD Million)
  • Table 35 Asia Pacific Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 36 Asia Pacific Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 37 Japan Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 38 Japan Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 39 China Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 40 China Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 41 India Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 42 India Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 43 South Korea Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 44 South Korea Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 45 Australia Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 46 Australia Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 47 Thailand Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 48 Thailand Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 49 Latin America Prediabetes Market, by Country, 2018 - 2030 (USD Million)
  • Table 50 Latin America Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 51 Latin America Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 52 Brazil Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 53 Brazil Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 54 Argentina Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 55 Argentina Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 56 Middle East & Africa Prediabetes Market, by Country, 2018 - 2030 (USD Million)
  • Table 57 Middle East & Africa Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 58 Middle East & Africa Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 59 South Africa Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 60 South Africa Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 61 Saudi Arabia Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 62 Saudi Arabia Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 63 UAE Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 64 UAE Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 65 Kuwait Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 66 Kuwait Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Prediabetes Market Segmentation
  • Fig. 2 Market Research Process
  • Fig. 3 Data Triangulation Techniques
  • Fig. 4 Primary Research Pattern
  • Fig. 5 Market Research Approaches
  • Fig. 6 Value-Chain-Based Sizing & Forecasting
  • Fig. 7 Market Formulation & Validation
  • Fig. 8 Market Snapshot
  • Fig. 9 Drug Class and Age Group Outlook (USD Million)
  • Fig. 10 Competitive Landscape
  • Fig. 11 Prediabetes Market Dynamics
  • Fig. 12 Prediabetes Market: Porter's Five Forces Analysis
  • Fig. 13 Prediabetes Market: PESTLE Analysis
  • Fig. 14 Prediabetes Market: Drug Class Segment Dashboard
  • Fig. 15 Prediabetes Market: Drug Class Market Share Analysis, 2024 & 2030
  • Fig. 16 Diguanide Market, 2018 - 2030 (USD Million)
  • Fig. 17 Thiazolidinediones Market, 2018 - 2030 (USD Million)
  • Fig. 18 Glucagon-like peptide-1 agonists (GLP-1) Market, 2018 - 2030 (USD Million)
  • Fig. 19 SGLT2 Inhibitors Market, 2018 - 2030 (USD Million)
  • Fig. 20 DPP-4 Inhibitors Market, 2018 - 2030 (USD Million)
  • Fig. 21 Others Market, 2018 - 2030 (USD Million)
  • Fig. 22 Prediabetes Market: Age Group Segment Dashboard
  • Fig. 23 Prediabetes Market: Age Group Market Share Analysis, 2024 & 2030
  • Fig. 24 Children (12-18 years) Market, 2018 - 2030 (USD Million)
  • Fig. 25 Adults (18-49) Market, 2018 - 2030 (USD Million)
  • Fig. 26 Elderly (50+) Market, 2018 - 2030 (USD Million)
  • Fig. 27 Prediabetes Market Revenue, By Region
  • Fig. 28 Regional Marketplace: Key Takeaways
  • Fig. 29 Regional Marketplace: Key Takeaways
  • Fig. 30 North America Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 31 U.S. Country Dynamics
  • Fig. 32 U.S. Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 33 Canada Country Dynamics
  • Fig. 34 Canada Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 35 Mexico Country Dynamics
  • Fig. 36 Mexico Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 37 Europe Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 38 UK Country Dynamics
  • Fig. 39 UK Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 40 Germany Country Dynamics
  • Fig. 41 Germany Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 42 France Country Dynamics
  • Fig. 43 France Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 44 Italy Country Dynamics
  • Fig. 45 Italy Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 46 Spain Country Dynamics
  • Fig. 47 Spain Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 48 Denmark Country Dynamics
  • Fig. 49 Denmark Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 50 Norway Country Dynamics
  • Fig. 51 Norway Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 52 Sweden Country Dynamics
  • Fig. 53 Sweden Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 54 Asia Pacific Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 55 Japan Country Dynamics
  • Fig. 56 Japan Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 57 China Country Dynamics
  • Fig. 58 China Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 59 India Country Dynamics
  • Fig. 60 India Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 61 South Korea Country Dynamics
  • Fig. 62 South Korea Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 63 Australia Country Dynamics
  • Fig. 64 Australia Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 65 Thailand Country Dynamics
  • Fig. 66 Thailand Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 67 Latin America Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 68 Brazil Country Dynamics
  • Fig. 69 Brazil Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 70 Argentina Country Dynamics
  • Fig. 71 Argentina Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 72 Middle East & Africa Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 73 South Africa Country Dynamics
  • Fig. 74 South Africa Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 75 Saudi Arabia Country Dynamics
  • Fig. 76 Saudi Arabia Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 77 UAE Country Dynamics
  • Fig. 78 UAE Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 79 Kuwait Key Country Dynamics
  • Fig. 80 Kuwait Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 81 Company Categorization
  • Fig. 82 Company Market Position Analysis
  • Fig. 83 Strategic Framework